Selective reduction in body fat mass and plasma leptin induced by angiotensin-converting enzyme inhibition in rats

Mathai, M. L., Naik, S., Sinclair, Andrew, Weisinger, H. S. and Weisinger, R. S. 2008, Selective reduction in body fat mass and plasma leptin induced by angiotensin-converting enzyme inhibition in rats, International journal of obesity, vol. 32, no. 10, pp. 1576-1584.

Attached Files
Name Description MIMEType Size Downloads

Title Selective reduction in body fat mass and plasma leptin induced by angiotensin-converting enzyme inhibition in rats
Author(s) Mathai, M. L.
Naik, S.
Sinclair, Andrew
Weisinger, H. S.
Weisinger, R. S.
Journal name International journal of obesity
Volume number 32
Issue number 10
Start page 1576
End page 1584
Total pages 9
Publisher Nature Publishing Group
Place of publication London, England
Publication date 2008-10
ISSN 0307-0565
1476-5497
Keyword(s) body composition
leptin
appetite
fat-free mass
Summary Objective: There is emerging evidence that angiotensin stimulates adipocyte differentiation and lipogenesis. This study tested the hypothesis that inhibition of angiotensin II by treatment with an angiotensin-converting enzyme inhibitor, perindopril, would reduce fat mass in rats. Design: After a 12-day baseline, rats were divided into two groups: one was untreated and the other received perindopril (1.2 mg kg−1 per day) in drinking water for 26 days.Subjects: In total, 16 male Sprague–Dawley rats aged 10 weeks at the start of the study. Measurements: Plasma leptin was measured in samples collected at baseline, half-way through and at the end of treatment. Body weight, food and water intake were measured daily throughout the experiment. Body fat mass, bone and lean mass were determined by dual energy X-ray absorptiometry (DEXA) at the end of the treatment period. Results: Daily food intake was the same in both groups throughout the study. By the end of treatment, animals receiving perindopril showed a modest reduction in weight gain relative to the untreated animals (62.4±5.0 g vs 73.0±4.0 g; P<0.05). DEXA analysis showed that body composition was greatly altered and the perindopril-treated group had 26% less body fat mass than the untreated group (61.0±5.2 g vs 44.4±4.2 g; P<0.01). The reduction in body fat mass was correlated with reductions in the weight of both the epididymal and retroperitoneal fat pads (P<0.001). Similarly, plasma leptin was reduced by perindopril treatment (4.64±0.56 ng ml−1) compared to the untreated group (8.27±1.03 ng ml−1; P<0.001). In contrast, there were no differences in lean or bone mass between the two groups.Conclusion: Oral treatment with perindopril selectively reduced body fat mass without influencing daily food intake. In contrast, there were no differences in lean or bone mass between the two groups
Language eng
Field of Research 110107 Metabolic Medicine
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1 Refereed article in a scholarly journal
HERDC collection year 2008
Copyright notice ©2008, Macmillan Publishers Limited
Persistent URL http://hdl.handle.net/10536/DRO/DU:30017661

Document type: Journal Article
Collection: School of Exercise and Nutrition Sciences
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 32 times in TR Web of Science
Scopus Citation Count Cited 33 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 360 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Fri, 14 Aug 2009, 13:55:47 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.